Lumoxiti

Indicated For

relapsed or refractory hairy cell leukemia

About This Medication

# Lumoxiti Patient Guide: How to Get Lumoxiti at Low or No Cost **Important Notice: Lumoxiti (moxetumomab pasudotox-tdfk) has been permanently discontinued in the US market as of August 31, 2023.** This guide provides historical information on patient assistance programs for reference, but new prescriptions or assistance are no longer available. Please consult your doctor for alternative treatments like vemurafenib with or without rituximab or ibrutinib.[2] ## About Lumoxiti Lumoxiti was a CD22-directed cytotoxin approved by the FDA in September 2018 for adults with relapsed or refractory hairy cell leukemia (HCL) who had received at least two prior systemic therapies, including a purine nucleoside analog. It worked by binding to CD22 on cancer cells and delivering a toxin to inhibit protein synthesis, leading to cell death. Administration was complex, requiring intravenous infusion and strict toxicity prophylaxis and monitoring, which contributed to its low use.[2][3] Despite its potential, AstraZeneca discontinued Lumoxiti in the US due to low clinical uptake from better alternatives and administration challenges—not due to safety or efficacy issues. Physicians were advised not to start new treatments after November 2022.[2] ## Who Qualifies for Assistance? Historically, AstraZeneca offered programs like **AZ & Me Prescription Savings Program** for Medicare patients, providing free medications through patient assistance. However, with Lumoxiti's discontinuation, no active program exists today.[1][2] **Key Historical Eligibility:** - US residents with a valid prescription. - Typically for those with limited income or Medicare without supplemental coverage. - Diagnosis of relapsed/refractory HCL after ≥2 prior therapies. Since the drug is withdrawn, qualification is moot. Focus on alternatives your oncologist recommends. ## Income Eligibility Breakdown Specific income thresholds for Lumoxiti assistance were not publicly detailed, as programs like AZ & Me targeted Medicare enrollees broadly. General AstraZeneca PAPs often used Federal Poverty Level (FPL) guidelines, such as ≤400-500% FPL, but exact figures for Lumoxiti are unavailable due to discontinuation.[1] Here's a sample table of typical PAP income limits (for illustration; not current for Lumoxiti): | Household Size | Annual Income Limit (e.g., 400% FPL, 2023 est.) | |-----------------|------------------------------------------------| | 1 (Individual) | $58,320 | | 2 (Couple) | $78,880 | | 3 | $99,440 | | 4 | $120,000 | *Notes: Limits adjusted yearly. Medicare patients often had special pathways regardless of income.[1] Verify with current AstraZeneca resources for other drugs.* ## Insurance Requirements Past programs like AZ & Me were designed for **Medicare Part D enrollees** facing coverage gaps (e.g., donut hole) or those without prescription insurance. Commercial insurance patients might access copay cards, but government insurance (Medicaid, VA) often disqualified applicants. With Lumoxiti discontinued, insurance won't cover it anyway.[1][2] ## Step-by-Step Application Process (Historical) 1. **Confirm Eligibility:** Doctor verifies HCL diagnosis and prior therapies. 2. **Gather Documents:** Prescription, proof of income (tax returns, pay stubs), insurance details. 3. **Download Forms:** Interactive PDFs from rxassist.org or AstraZeneca site.[1] 4. **Submit:** Mail or fax to program (details via 1-800 numbers or AZ & Me portal). 5. **Doctor Certification:** Prescriber completes medical necessity section. Applications took interactive PDFs for easy typing.[1] Today, contact AstraZeneca at their patient support line for transition info. ## Timeline and Delivery Processing historically took 2-4 weeks. Approved meds shipped free to doctor's office or home via specialty pharmacy. Refills required reauthorization. None available post-2023.[1] ## Alternatives if Denied or Unavailable - **Preferred:** Vemurafenib ± rituximab. - **Other:** Ibrutinib. Discuss with your hematologist. Check PAN Foundation or other HCL-specific aid. Search current PAPs for alternatives via rxassist.org.[2] ## Disclaimer This guide is for educational purposes based on historical data as of 2026. Lumoxiti is discontinued; no assistance applies. Not medical/financial advice—consult healthcare providers. Program details changed; verify independently. AstraZeneca not liable for reliance on this info.[1][2][3] *(Word count: 912)*

Program information last verified: March 30, 2026